Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Phase II study of thalidomide in patients with metastatic melanoma.

Pawlak WZ, Legha SS.

Melanoma Res. 2004 Feb;14(1):57-62.

PMID:
15091195
2.

A phase II study of thalidomide in patients with brain metastases from malignant melanoma.

Vestermark LW, Larsen S, Lindeløv B, Bastholt L.

Acta Oncol. 2008;47(8):1526-30. doi: 10.1080/02841860801918521.

PMID:
18607876
3.

Phase II study of thalidomide in patients with metastatic malignant melanoma.

Reiriz AB, Richter MF, Fernandes S, Cancela AI, Costa TD, Di Leone LP, Schwartsmann G.

Melanoma Res. 2004 Dec;14(6):527-31.

PMID:
15577325
4.

Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.

Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.

Chemotherapy. 2009;55(4):221-7. doi: 10.1159/000219435. Epub 2009 May 19.

PMID:
19451711
5.

A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.

Laber DA, Okeke RI, Arce-Lara C, Taft BS, Schonard CL, McMasters KM, Kloecker GH, Miller DM.

J Cancer Res Clin Oncol. 2006 Sep;132(9):611-6. Epub 2006 Jun 2.

PMID:
16741726
6.

Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.

García M, del Muro XG, Tres A, Crespo C, Valladares M, López JJ, Rifà J, Pérez X, Filipovich E, Germà-Lluch JR.

Melanoma Res. 2006 Aug;16(4):365-70.

PMID:
16845333
7.

A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.

Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP.

Oncologist. 2005 Jun-Jul;10(6):392-8.

8.

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.

Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.

Cancer. 2005 Jun 15;103(12):2590-7.

9.

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.

Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L.

Cancer. 2005 Jan 1;103(1):119-25.

10.

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.

Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.

J Clin Oncol. 2003 Sep 1;21(17):3351-6.

PMID:
12947072
11.

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.

Varker KA, Campbell J, Shah MH.

Cancer Chemother Pharmacol. 2008 Apr;61(4):661-8. Epub 2007 Jun 23.

PMID:
17589846
12.

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.

Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B, Margolin KA.

Cancer. 2008 Oct 15;113(8):2139-45. doi: 10.1002/cncr.23805.

13.

Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.

Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T.

Melanoma Res. 2004 Feb;14(1):63-6.

PMID:
15091196
14.

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.

Masucci GV, Månsson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J.

Melanoma Res. 2006 Aug;16(4):357-63.

PMID:
16845332
15.
16.

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.

Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.

Cancer. 2006 Jun 1;106(11):2445-51.

17.

Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.

Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM.

Urology. 2004 Jun;63(6):1061-5.

PMID:
15183950
18.

A phase II study of bortezomib in the treatment of metastatic malignant melanoma.

Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C.

Cancer. 2005 Jun 15;103(12):2584-9.

19.

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.

Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R.

Cancer. 2002 Aug 15;95(4):758-65.

20.

Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer.

Morabito A, Carillio G, Longo R, Gasparini G.

Cancer J. 2005 May-Jun;11(3):248-51.

PMID:
16053669
Items per page

Supplemental Content

Write to the Help Desk